Cytek Biosciences, Inc. CTKB
Set alert
As of Nov 2, 10:55 AM ET
- YTD
- +15.98%
- 1 year
- +50.18%
- Open
- 6.19
- Prev close
- 6.13
- Mkt cap
- 761.05M
- Vol
- 329.80K
- Avg vol
- 1.21M
- EPS
- -0.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.86
- High
- 6.19
- Forward P/E
- 107.67
- Beta
- 1.32
- Short ratio
- 4.50
- Inst. own
- 59.02%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 6, 2024
- 50-d avg
- 6.03
- 200-d avg
- 5.92
- 1y target
- 8.40
News
3 days ago globenewswire.com
Cytek Biosciences to Participate in Upcoming Investor Conferences
FREMONT, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the…
5 days ago zacks.com
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
Cytek Biosciences (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 week ago globenewswire.com
Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
FREMONT, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the third quarter…
3 weeks ago defenseworld.net
Cytek Biosciences (NASDAQ:CTKB) Sets New 12-Month High – Here’s What Happened
Cytek Biosciences, Inc. (NASDAQ: CTKB - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $6.21 and last traded at $5.9950, with a volume of…
1 month ago defenseworld.net
1,315,332 Shares in Cytek Biosciences, Inc. $CTKB Acquired by Bank of America Corp DE
Bank of America Corp DE purchased a new position in shares of Cytek Biosciences, Inc. (NASDAQ: CTKB) during the undefined quarter, according to the company in its most recent filing with the…
1 month ago globenewswire.com
Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
Cytek has expanded its Cytek® Cloud digital ecosystem with a new Cloud Analysis tool to create the industry's first end-to-end flow cytometry platform.
1 month ago defenseworld.net
Critical Survey: Revvity (NYSE:RVTY) vs. Cytek Biosciences (NASDAQ:CTKB)
Revvity (NYSE: RVTY - Get Free Report) and Cytek Biosciences (NASDAQ: CTKB - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies…
1 month ago zacks.com
Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
Investors need to pay close attention to CTKB stock based on the movements in the options market lately.
1 month ago seekingalpha.com
Cytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Cytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago globenewswire.com
Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
FREMONT, Calif., and HAMBURG, Germany, Sept.
1 month ago globenewswire.com
Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS
FREMONT, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- As clinical laboratories seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow…
2 months ago defenseworld.net
Deutsche Bank AG Makes New $496,000 Investment in Cytek Biosciences, Inc. $CTKB
Deutsche Bank AG bought a new position in Cytek Biosciences, Inc. (NASDAQ: CTKB) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund…
2 months ago globenewswire.com
Cytek Biosciences to Participate in Upcoming Investor Conferences
FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the…
-
2 months ago benzinga.com
Cytek Biosciences Says Jury Finds In Cytek’s Favor On Three Of Four Asserted Patent Claims; To Challenge Remaining Finding; Jury Awarded Past Damages Consisting Of $20M In Lost Profits And $36M In Royalties
Cytek Biosciences, Inc. ("Cytek Biosciences," "Cytek," or the "Company") (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that a jury in the United States District Court
2 months ago globenewswire.com
Jury Finds in Cytek's Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced…
2 months ago seekingalpha.com
Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript
Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Cytek Biosciences Q2 Earnings Call Highlights
Cytek Biosciences NASDAQ: CTKB reported second-quarter 2026 revenue growth of 6% year over year, supported by double-digit gains in the United States and China, while continued weakness in Europe and…
2 months ago zacks.com
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.01 per share a year ago.
-
2 months ago benzinga.com
Cytek Biosciences Q2 EPS $(0.09), Inline, Sales $48.140M Miss $48.610M Estimate
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 125 percent decrease over losses of $(0.04) per share from the same…
-
2 months ago benzinga.com
Cytek Biosciences Raises FY2026 Sales Guidance from $205.000M-$212.000M to $207.000M-$212.000M vs $208.767M Est
Cytek Biosciences (NASDAQ:CTKB) raises FY2026 sales outlook from $205.000 million-$212.000 million to $207.000 million-$212.000 million vs $208.767 million estimate.
2 months ago globenewswire.com
Cytek Biosciences Reports Second Quarter 2026 Financial Results
FREMONT, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results…
3 months ago zacks.com
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
Cytek Biosciences (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 months ago zacks.com
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.
3 months ago benzinga.com
Ryanair Posts Weak Q1 Results, Joins HDFC Bank And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
US stock futures higher with Nasdaq 100 up 150 points. Ryanair (RYAAY) shares fall after weak Q1 results. Other stocks declining in pre-market.
5 months ago benzinga.com
Concrete Pumping Holdings Reports Blowout Q2 Results, Joins ServiceTitan and Other Big Stocks Moving Higher in Friday's Pre-Market Session
US stock futures higher, Nasdaq futures down. Concrete Pumping Holdings shares up 28.94% pre-market. Other stocks moving in pre-market.
5 months ago benzinga.com
Braze Posts Mixed Q1 Results, Joins Sidus Space, Everpure And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
US stock futures lower, Braze Inc (BRZE) shares drop 8.4% in pre-market trading after reporting mixed Q1 results. Other stocks also down.
5 months ago benzinga.com
Why Phreesia Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket
Phreesia (NYSE: PHR) shares rose in pre-market trading after better-than-expected sales results. Other gainers include Snowflake, Genius Group, and Astrotech.
-
5 months ago benzinga.com
Stephens & Co. Maintains Overweight on Cytek Biosciences, Lowers Price Target to $4.75
Stephens & Co. analyst Mason Carrico maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $5.5 to $4.75.
-
5 months ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $5.5
Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight and lowers the price target from $6 to $5.5.
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
5 months ago benzinga.com
Cytek Biosciences Affirms FY2026 Sales Guidance of $205.000M-$212.000M vs $208.235M Est
Cytek Biosciences (NASDAQ:CTKB) affirms FY2026 sales outlook from $205.000 million-$212.000 million to $205.000 million-$212.000 million vs $208.235 million estimate.
-
5 months ago benzinga.com
Cytek Biosciences Q1 EPS $(0.15) Misses $(0.10) Estimate, Sales $44.135M Miss $44.328M Estimate
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.10) by 50 percent. This is a 66.67 percent decrease over losses of…
-
8 months ago benzinga.com
Cytek Biosciences Sees FY2026 Sales $205.000M-$212.000M vs $207.058M Est
Cytek Biosciences (NASDAQ:CTKB) sees FY2026 sales of $205.000 million-$212.000 million vs $207.058 million analyst estimate.
8 months ago benzinga.com
Earnings Breakdown: Cytek Biosciences Q4
Earnings Breakdown: Cytek Biosciences Q4
-
8 months ago benzinga.com
Cytek Biosciences Q4 EPS $(0.34) Misses $(0.02) Estimate, Sales $62.141M Beat $57.187M Estimate
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.02) by 1378.26 percent. This is a 585.71 percent decrease over…
8 months ago benzinga.com
Earnings Scheduled For February 26, 2026
Earnings Scheduled For February 26, 2026
-
9 months ago benzinga.com
Cytek Sees $62M Q4 Revenue Vs $56.99M Est, Forecasts About $201M in Full-Year 2025 Sales Vs $196.71M Est
Cytek Biosciences, Inc. (NASDAQ: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the fourth quarter and full year ended December 31,…
-
9 months ago benzinga.com
TD Cowen Maintains Buy on Cytek Biosciences, Raises Price Target to $5
TD Cowen analyst Brendan Smith maintains Cytek Biosciences (NASDAQ:CTKB) with a Buy and raises the price target from $4 to $5.
11 months ago benzinga.com
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday
-
11 months ago benzinga.com
Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $7.5
Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $8 to $7.5.
-
12 months ago benzinga.com
Cytek Biosciences Affirms FY2025 Sales Guidance of $196.000M-$205.000M vs $196.252M Est
Cytek Biosciences (NASDAQ:CTKB) affirms FY2025 sales outlook from $196.000 million-$205.000 million to $196.000 million-$205.000 million vs $196.252 million estimate.
-
12 months ago benzinga.com
Cytek Biosciences Q3 EPS $(0.04) Beats $(0.05) Estimate, Sales $52.293M Beat $51.489M Estimate
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 500 percent decrease over earnings of…
12 months ago benzinga.com
Earnings Scheduled For November 5, 2025
Earnings Scheduled For November 5, 2025
-
1 year ago benzinga.com
Cytek Biosciences Announces The Relocation Of Its European Headquarters To A New Facility In Amsterdam's Life Sciences District
FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operations and enhances service for its customers, spectral flow cytometry leader Cytek Biosciences, Inc.…
-
1 year ago benzinga.com
Cytek Biosciences Narrows FY2025 Sales Guidance from $196.000M-$210.000M to $196.000M-$205.000M vs $198.301M Est
Cytek Biosciences (NASDAQ:CTKB) narrows FY2025 sales outlook from $196.000 million-$210.000 million to $196.000 million-$205.000 million vs $198.301 million estimate.
-
1 year ago benzinga.com
Cytek Biosciences Q2 EPS $(0.04), Inline, Sales $45.602M Miss $46.479M Estimate
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.08) per share from the same…
-
1 year ago benzinga.com
Beyond The Numbers: 4 Analysts Discuss Cytek Biosciences Stock
Beyond The Numbers: 4 Analysts Discuss Cytek Biosciences Stock
-
1 year ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $7
Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight and lowers the price target from $9 to $7.